[1]李春生.倍他乐克联合胺碘酮治疗阵发性房颤的疗效及对尿酸、SIRT1水平的影响[J].医学信息,2022,35(18):87-89.[doi:10.3969/j.issn.1006-1959.2022.18.022]
　LI Chun-sheng.Efficacy of Betaloc Combined with Amiodarone in the Treatment of Paroxysmal Atrial Fibrillation and its Effect on Uric Acid and SIRT1 Levels[J].Journal of Medical Information,2022,35(18):87-89.[doi:10.3969/j.issn.1006-1959.2022.18.022]
点击复制

倍他乐克联合胺碘酮治疗阵发性房颤的疗效及对尿酸、SIRT1水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
87-89
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
Efficacy of Betaloc Combined with Amiodarone in the Treatment of Paroxysmal Atrial Fibrillation and its Effect on Uric Acid and SIRT1 Levels
文章编号:
1006-1959（2022）18-0087-03
作者:
李春生
（南丰县中医院内一科，江西 南丰 344500）
Author(s):
LI Chun-sheng
(Department of Internal Medicine,Nanfeng County Hospital of Traditional Chinese Medicine,Nanfeng 344500,Jiangxi,China)
关键词:
倍他乐克; 胺碘酮; 阵发性房颤; 尿酸; SIRT1
Keywords:
Betaloc; Amiodarone; Paroxysmal atrial fibrillation; Uric acid; SIRT1
分类号:
R541.7+5
DOI:
10.3969/j.issn.1006-1959.2022.18.022
文献标志码:
A
摘要:
目的 探讨倍他乐克联合胺碘酮治疗阵发性房颤的疗效及对尿酸、SIRT1水平的影响。方法 选取2019年6月-2020年6月我院接治疗的阵发性房颤病患者120例，根据随机数字表法分为胺碘酮组和倍他乐克组，每组60例。两组均给予常规基础治疗，胺碘酮组在常规治疗基础上给予胺碘酮，倍他乐克组在胺碘酮组基础上给予倍他乐克治疗。比较两组临床疗效、房颤发作情况（房颤发作次数及持续时间）、尿酸与SIRT1水平及不良反应发生情况。结果 倍他乐克组总有效率为85.00%，高于胺碘酮组的65.00%，差异有统计学意义（P＜0.05）；倍他乐克组房颤发作次数少于胺碘酮组，房颤持续时间短于胺碘酮组，差异有统计学意义（P＜0.05）；倍他乐克组尿酸与SIRT1水平低于胺碘酮组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 倍他乐克联合胺碘酮治疗阵发性房颤的效果确切，可有效改善患者临床症状，降低血液尿酸及SIRT1水平表达，且联合治疗不增加不良反应发生风险，安全性较好。
Abstract:
Objective To investigate the efficacy of betaloc combined with amiodarone in the treatment of paroxysmal atrial fibrillation and its effect on uric acid and SIRT1 levels.Methods A total of 120 patients with paroxysmal atrial fibrillation treated in our hospital from June 2019 to June 2020 were selected and divided into amiodarone group and betaloc group according to the random number table method, with 60 cases in each group. Both groups were given routine basic treatment, amiodarone group was given amiodarone on the basis of routine treatment, betaloc group was given betaloc on the basis of amiodarone group. The clinical efficacy, atrial fibrillation attack (number and duration of atrial fibrillation attack), uric acid and SIRT1 levels and adverse reactions were compared between the two groups.Results The total effective rate of betaloc group was 85.00%, which was higher than 65.00% of amiodarone group, the difference was statistically significant (P<0.05). The number of atrial fibrillation episodes in the betaloc group was less than that in the amiodarone group, and the duration of atrial fibrillation was shorter than that in the amiodarone group, the difference was statistically significant (P<0.05). The levels of uric acid and SIRT1 in betaloc group were lower than those in amiodarone group, and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Betaloc combined with amiodarone is effective in the treatment of paroxysmal atrial fibrillation. It can effectively improve the clinical symptoms of patients, reduce the expression of blood uric acid and SIRT1 levels, and the combined treatment does not increase the risk of adverse reactions.

参考文献/References:

[1]庹田,张欣,程亚玲,等.参松养心胶囊联合缬沙坦治疗阵发性房颤对窦性心律维持、左房功能的影响[J].中华中医药学刊,2020,38(2):251-254.[2]李凡,夏珍,俞建华,等.尼非卡兰在心房颤动患者射频消融术后转复的疗效观察[J].中华心血管病杂志,2019,47(12):963-968. [3]常娟,周素锋,张伟.钙离子通道基因异常介导的心房颤动电生理特征和分子机制[J].基因组学与应用生物学,2019,38(10):4806-4811.[4]冶敦清,祁国荣,路霖,等.MicroRNA-155/FOXO3a在心脏手术后心房颤动患者心房组织中的表达及与心房纤维化的关系[J].中国现代医学杂志,2020,30(8):40-44.[5]叶生爱,于裕,郁大江,等.右室临时起搏联合β-受体阻滞剂治疗成人心脏术后难治性室性心律失常的疗效观察[J].中国实用医刊,2017,44(6):4-8.[6]周晓凯,龚婵娟,方印.静脉应用胺碘酮对胸腔镜下持续性心房颤动射频消融术后复律作用的影响[J].南京医科大学学报(自然科学版),2020,40(11):1668-1671,1691.[7]谢虹,周川.阿托伐他汀钙联合胺碘酮及华法林治疗阵发性房颤的临床疗效及对患者心功能和预后复发的影响[J].贵州医药,2021,45(6):873-874. [8]王春颖.观察小剂量胺碘酮与倍他乐克治疗老年性房颤的临床效果[J].黑龙江中医药,2021,50(3):60-61.[9]石雪,陶涛,张克军.倍他乐克对阵发性心房颤动患者干预作用分析[J].贵州医药,2020,44(6):881-882.[10]覃凯,苏晓琳,曾凤兰,等.预激综合征合并阵发性心房颤动采用导管射频消融术治疗的临床疗效分析[J].临床心血管病杂志,2020,324(6):49-52.[11]徐娟,李晓旋,辛恺,等.自动功能成像技术评价左室射血分数正常房颤患者的左室收缩功能[J].中国临床医学影像杂志,2020,31(4):258-260,280.[12]赵子明,袁义强,尹晓盟,等.持续性心房颤动射频消融术后抗心律失常药物应用时程与预后的相关性分析[J].临床心血管病杂志,2019,35(1):60-64.[13]罗红敏.导管消融与抗心律失常药物治疗对心房颤动患者生活质量的影响:一项随机对照临床试验[J].中华危重病急救医学,2019(6):784.[14]吴琦.肥厚型心肌病合并心房颤动的临床情况分析[D].广州:南方医科大学,2021.[15]江珍珍.β-受体阻滞剂对持续性房颤患者运动心率增幅影响的临床研究[D].南昌:南昌大学(医学院),2020.[16]热依拉·阿布来提,哈斯达尔·米地里别克.胺碘酮对心律失常患者炎性因子、心功能及心率变异性的影响[J].农垦医学,2021,43(1):26-28.[17]刘斌,王霞,唐兵梅,等.胺碘酮联合阿替普酶溶栓治疗老年急性心肌梗死的临床观察[J].中国老年学杂志,2020,40(2):240-243.[18]彭燕飞,宋初平.倍他乐克缓释片较倍他乐克平片对慢性充血性心力衰竭治疗优势[J].湖南师范大学学报(医学版),2020,17(2):106-109.[19]冯韩章,赵娟,杨渊博.胺碘酮联合倍他乐克对心肌梗死患者心功能及不良反应的影响[J].中国临床医生杂志,2020,48(11):38-41.[20]陈强,李俊萍,郭晓华.稳心颗粒联合倍他乐克治疗老年阵发性心房颤动的疗效[J].包头医学院学报,2016,32(10):21-22.

相似文献/References:

[1]张华光.倍他乐克联合胺碘酮治疗顽固性室性早搏的疗效分析[J].医学信息,2018,31(05):128.[doi:10.3969/j.issn.1006-1959.2018.05.045]
　ZHANG Hua-guang.Efficacy of Betaloc Combined with Amiodarone in the Treatment of Intractable Ventricular Premature Beats[J].Journal of Medical Information,2018,31(18):128.[doi:10.3969/j.issn.1006-1959.2018.05.045]
[2]冯彩云.胺碘酮导致间质性肺病患者的1例分析[J].医学信息,2018,31(10):191.[doi:10.3969/j.issn.1006-1959.2018.10.068]
[3]陶春艳.柔性护理在胺碘酮治疗心房颤动护理中的应用研究[J].医学信息,2018,31(24):154.[doi:10.3969/j.issn.1006-1959.2018.24.046]
　TAO Chun-yan.Application of Flexible Nursing in the Treatment of Atrial Fibrillation with Amiodarone[J].Journal of Medical Information,2018,31(18):154.[doi:10.3969/j.issn.1006-1959.2018.24.046]
[4]李杰华.急诊应用胺碘酮联合门冬氨酸钾镁治疗冠心病快速心律失常的疗效[J].医学信息,2020,33(05):154.[doi:10.3969/j.issn.1006-1959.2020.05.050]
　LI Jie-hua.Treatment of Rapid Arrhythmia in Coronary Heart Disease with Amiodarone Combined with Potassium Magnesium Aspartate[J].Journal of Medical Information,2020,33(18):154.[doi:10.3969/j.issn.1006-1959.2020.05.050]
[5]孙 健.小剂量胺碘酮与美托洛尔治疗老年性房颤的效果及对左心房和心功能的影响[J].医学信息,2022,35(18):105.[doi:10.3969/j.issn.1006-1959.2022.18.028]
　SUN Jian.The Effect of Low-dose Amiodarone and Metoprolol in the Treatment of Senile Atrial Fibrillation and its Effect on Left Atrial and Cardiac Function[J].Journal of Medical Information,2022,35(18):105.[doi:10.3969/j.issn.1006-1959.2022.18.028]
[6]李知生.胺碘酮联合利多卡因治疗急性心梗伴室性心律失常的临床疗效[J].医学信息,2020,33(11):149.[doi:10.3969/j.issn.1006-1959.2020.11.048]
　LI Zhi-sheng.Amiodarone Combined with Lidocaine in the Treatment of Acute Myocardial Infarction with Ventricular Arrhythmia[J].Journal of Medical Information,2020,33(18):149.[doi:10.3969/j.issn.1006-1959.2020.11.048]
[7]蒲军亮,张 婷.沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性心力衰竭的疗效观察[J].医学信息,2020,33(14):159.[doi:10.3969/j.issn.1006-1959.2020.14.051]
　PU Jun-liang,ZHANG Ting.Observation of Sacubitril Valsartan Sodium Tablets Combined with Metoprolol Succinate Sustained-release Tablets in the Treatment of Chronic Heart Failure[J].Journal of Medical Information,2020,33(18):159.[doi:10.3969/j.issn.1006-1959.2020.14.051]
[8]张宗艳,赵 晖,高 超,等.胺碘酮联合琥珀酸美托洛尔缓释片急诊治疗室性心律失常的疗效[J].医学信息,2020,33(19):145.[doi:10.3969/j.issn.1006-1959.2020.19.045]
　ZHANG Zong-yan,ZHAO Hui,GAO Chao,et al.Efficacy of Amiodarone Combined with Metoprolol Succinate Sustained-release Tablets in Emergency Treatment of Ventricular Arrhythmia[J].Journal of Medical Information,2020,33(18):145.[doi:10.3969/j.issn.1006-1959.2020.19.045]
[9]蔺洪萌.胺碘酮联合西地兰治疗冠心病合并心律失常的疗效[J].医学信息,2021,34(20):161.[doi:10.3969/j.issn.1006-1959.2021.20.043]
　LIN Hong-meng.Effect of Amiodarone Combined with Cedilanid on Coronary Heart Disease Complicated with Arrhythmia[J].Journal of Medical Information,2021,34(18):161.[doi:10.3969/j.issn.1006-1959.2021.20.043]

更新日期/Last Update: 1900-01-01